Abpro

About:

Abpro is a biotechnology company focused on therapeutics, diagnostics, and research.

Website: https://abpro.com

Twitter/X: abprolabs

Top Investors: Celltrion

Description:

Abpro is a biotechnology company dedicated to accelerating biological research by providing superior tools to researchers worldwide. As a pioneer of industrial biochemistry and an emerging leader in the reagents field, they have developed a proprietary technology platform that allows for faster, more efficient production of recombinant proteins and antibodies. As a result, Abpro delivers superior quality products at industry-leading speeds. Abpro leveraging these platforms, both independently and through collaborations with global pharmaceutical companies and research institutions to develop therapeutic antibodies for use in immuno-oncology, ophthalmology, and other disease areas. The DiversImmune platform enables the generation of novel antibodies and next-generation antibody therapies.

Total Funding Amount:

$40.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Woburn, Massachusetts, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)abpro-labs.com

Founders:

Eugene Cha, Ian Chan

Number of Employees:

11-50

Last Funding Date:

2024-11-13

IPO Status:

Public

Industries:

© 2025 bioDAO.ai